IQM Quantum Computers Unveils Development Roadmap Focused on Fault-tolerant Quantum Computing by 2030
IQM's development roadmap aims to achieve fault-tolerance by 2030 and outlines a path to scaling up to 1 million qubits with combined quantum error reduction and error correction. The roadmap is underpinned by merging IQM's two processor topologies Star and Crystal for hardware efficient error correction as well as an open modular software stack for HPC integration. IQM also demonstrates early industry use cases in quantum machine learning, simulation of quantum systems and optimization.
IQM Quantum Computers (IQM), a global leader in superconducting quantum computing, today announced its development roadmap with technical milestones targeting fault tolerant quantum computing by 2030, while enabling a dedicated Noisy Intermediate-Scale Quantum (NISQ) approach for near-term usage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113963297/en/
IQM Quantum Computers Development Roadmap (Graphic: Business Wire)
Since its start, IQM has successfully delivered full-stack quantum computers based on its first three processor generations. IQM's 12-year roadmap reflects its vision for pioneering quantum solutions through novel algorithmic approaches, modular software integration, and scalable hardware advancements. It leverages the company's ability to design and fabricate next-generation quantum processors with seamless integration into full-stack systems controlled by an open software stack.
IQM's unique co-design capabilities steer the roadmap towards efficient error-correction implementations with high system performance by merging IQM's two processor topologies IQM Star and IQM Crystal. To enable the roadmap, IQM systematically invests in its R&D, testing and fabrication facilities to boost technology scaling up to 1 million qubits while maintaining high qubit quality and gate fidelity.
To support the developer community and to ease the usage of quantum computing, IQM will also enable tight high-performance computing (HPC) integration and create a special software development kit (SDK). Open interfaces will empower the ecosystem, including quantum error mitigation, co-develop libraries and use-cases on IQM’s quantum computers.
The company aims to achieve quantum advantage across multiple industry domains, focusing on quantum simulations, optimization, and quantum machine learning. According to a McKinsey report, these selected use-cases will unlock a value potential of more than US$28 billion by 2035.
Quantum advantage will be provided by fully error-corrected systems with hundreds to thousands of high-precision logical qubits, for which error correction will be enabled by efficiently implementing novel quantum low-density parity-check (QLDPC) codes. This approach reduces the hardware overhead by a factor of up to 10 compared to surface code implementation.
Furthermore, IQM is targeting high-precision logical qubits with error rates below 10^-7, enabling quantum advantage for applications demanding exceptional accuracy, such as in chemistry and materials science.
“We are implementing Quantum low-density parity-check (QLDPC) codes through a novel chip topology, enabled by our uniquely connected Star topology, long-distance couplers and a very compact approach for advanced packaging and signal routing,” said Dr. Jan Goetz, Co-Founder and Co-CEO of IQM Quantum Computers. “This underlines our commitment to hardware efficiency, enabling a feasible and scalable pathway to fault tolerance combined with an open and modular software architecture.”
Goetz emphasizes that the company’s proprietary cleanroom facilities will support the fabrication of complex processors with unique long-range connections, facilitating high-performance quantum processors.
To this end, IQM will implement novel solutions for advanced packaging and 3D integration to ensure scalability while maintaining its ambitious goals to reduce error rates, while its large-scale processors will be built up in a modular way and powered by cryogenic electronics. The results are reduced heat load, strongly miniaturized packaging solutions, and reduced cost per qubit. These features will result in more performant and affordable products for IQM's customers in the HPC and enterprise market.
Offering on-premises and cloud access, IQM has been specializing in integrating quantum systems into HPC centers since 2020. The latest is Germany’s first hybrid quantum computer at the Leibniz Supercomputing Centre.
IQM aims to explain further details of the roadmap in future publications, blog posts, and at industry and academic events.
About IQM Quantum Computers:
IQM is a global leader in designing, building, and selling superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers anywhere in the world. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 280 employees with offices in Espoo, Madrid, Munich, Paris, Palo Alto, Singapore and Warsaw.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113963297/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press release
SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 HighlightsTotal revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase of
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press release
Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This
Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment13.11.2024 15:30:00 CET | Press release
Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. Medidata Rave CTMS leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant visibility for study teams, Rave CTMS streamlines collaboration, eliminates manual data entry, and accelerates trial timelines with exceptional accuracy. “We are honored to be recognized as the highest leader in CTMS by Everest Group,” said Tom Doyle, chief technology officer, Medidata. “This accolade underscores our unwavering commitment to transforming research and reaffirms our strategy to deliver
China Moutai Showcases Ecology Promotion Practices at the China Pavilion During COP2913.11.2024 15:05:00 CET | Press release
At a side event titled "Ecological Civilization and Beautiful China Practices" during the 2024 UN Climate Change Conference (COP29) in Baku, Azerbaijan, China Moutai showcased its commitment to ecological sustainability and called for greater attention to climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113718721/en/ Li Wang, General Manager of China Moutai Group, presented at the side event in Baku. (Photo: Business Wire) Li Wang, General Manager of China Moutai Group, emphasized that Chinese modernization is rooted in achieving harmony between humanity and nature. She said that as a representative of China’s liquor industry, Moutai has embraced the principle that "lucid waters and lush mountains are invaluable assets." This philosophy underscores the company’s approach to modernization, which prioritizes environmental stewardship. Wang highlighted Moutai Group’s dedication to leveraging regional ecological
Appeals Court Confirms Conviction of Intercos Korea in Kolmar Korea Tech Theft13.11.2024 15:00:00 CET | Press release
Intercos Korea to be held criminally liable for leaking and misusing Kolmar Korea’s trade secrets Kolmar Korea (KRX: 161890) has won the victory in the remand trial against Intercos Korea, the Korean subsidiary of Italian cosmetics firm Intercos, concerning the misappropriation of its core sunscreen technology. The latest ruling has confirmed Intercos Korea is guilty of stealing Kolmar Korea’s technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113259255/en/ Kolmar Korea R&D Complex (photo: Kolmar Holdings) The 3-2 Criminal Division of the Suwon District Court sentenced a fine of KRW 5 million on Intercos Korea for breaching the Unfair Competition Prevention and Trade Secret Protection Act on October 18. While the court reduced the fine from an initial KRW 10 million to KRW 5 million, it upheld the conviction of Intercos Korea. The ruling became final as Intercos Korea opted not to file an appeal. Intercos Korea wa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom